Citation Impact
Citing Papers
Vascular Klotho Deficiency Potentiates the Development of Human Artery Calcification and Mediates Resistance to Fibroblast Growth Factor 23
2012 Standout
KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)
2009 Standout
Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging
2023 Standout
Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters
2017 Standout
Regulation of the Voltage Gated K<sup>+</sup> Channel K<sub>v1.3</sub> by Recombinant Human Klotho Protein
2014 Standout
Bisphenol A and human health: A review of the literature
2013 Standout
Vitamin D deficiency and toxicity in chronic kidney disease: in search of the therapeutic window
2010
Mortality risk among hemodialysis patients receiving different vitamin D analogs
2006
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis
2008 Standout
The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats
2007
Vitamin D Metabolism, Mechanism of Action, and Clinical Applications
2014 Standout
Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis
2016 Standout
Cinacalcet HCl and Concurrent Low-dose Vitamin D Improves Treatment of Secondary Hyperparathyroidism in Dialysis Patients Compared with Vitamin D Alone
2008
1,25-(OH)<sub>2</sub>-16ene-23yne-D<sub>3</sub> Reduces Secondary Hyperparathyroidism in Uremic Rats with Little Calcemic Effect
2003
Vitamin D analogs: Therapeutic applications and mechanisms for selectivity
2008
Paricalcitol Attenuates Renal Interstitial Fibrosis in Obstructive Nephropathy
2006
Vitamin D Receptor Activators Can Protect against Vascular Calcification
2008
Cellular and molecular mechanisms of renal fibrosis
2011 Standout
Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy
2009
Klotho Deficiency Causes Vascular Calcification in Chronic Kidney Disease
2010 Standout
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
2006 Standout
Treatment of chronic kidney disease
2011
Impact of Activated Vitamin D and Race on Survival among Hemodialysis Patients
2008
Improving the efficacy of RAAS blockade in patients with chronic kidney disease
2012
PHOSPHORUS METABOLISM AND MANAGEMENT IN CHRONIC KIDNEY DISEASE: Renal Osteodystrophy, Phosphate Homeostasis, and Vascular Calcification
2007
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
2013 Standout
Vitamin D in Chronic Kidney Disease: New Potential for Intervention
2010
Calcitriol Supplementation Improves Endothelium-Dependent Vasodilation in Rat Hypertensive Renal Injury
2014
Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis
2005
Oxidative stress in chronic kidney disease
2018 Standout
Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)
2006 Standout
Activated Injectable Vitamin D and Hemodialysis Survival
2005
Paricalcitol Capsule for the Treatment of Secondary Hyperparathyroidism in Stages 3 and 4 CKD
2006
Vitamin D and its analogues: Do they protect against cardiovascular disease in patients with kidney disease?
2005
Role of Hyperphosphatemia and 1,25-Dihydroxyvitamin D in Vascular Calcification and Mortality in Fibroblastic Growth Factor 23 Null Mice
2007
Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism
2010
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
2013 Standout
Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy
2004
Chronic Kidney Disease
2016 Standout
Achieving NKF-K/DOQI™ bone metabolism and disease treatment goals with cinacalcet HCl
2005
Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients With Chronic Kidney Disease
2011 Standout
Meta-analysis: Vitamin D Compounds in Chronic Kidney Disease
2007
Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients
2014
Effect of combining an ACE inhibitor and a VDR activator on glomerulosclerosis, proteinuria, and renal oxidative stress in uremic rats
2011
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
2016 Standout
Vitamin D and Immune Function
2013 Standout
Hormones and Endocrine-Disrupting Chemicals: Low-Dose Effects and Nonmonotonic Dose Responses
2012 Standout
Fibrosis — A Common Pathway to Organ Injury and Failure
2015 Standout
Vitamin D compounds for people with chronic kidney disease requiring dialysis
2009
Differential Effects of Vitamin D Analogs on Vascular Calcification
2007
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
2016 Standout
Role of Renal Angiotensin II Type 1 Receptors in the Genesis of Hypertension
2007 StandoutNobel
Works of Michael Amdahl being referenced
Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings
2004
Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study
2012
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial
2010
Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism
2003
Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study design and baseline characteristics of the IMPACT SHPT study
2011
The Selective Vitamin D Receptor Activator for Albuminuria Lowering (VITAL) Study: Study Design and Baseline Characteristics
2009
Paricalcitol dosing according to body weight or severity of hyperparathyroidism: A double-blind, multicenter, randomized study
2001
Intravenous Paricalcitol for Treatment of Secondary Hyperparathyroidism in Children on Hemodialysis
2007